US equities
|
NVDA
$164.96
▼-5.05%
AMD
$580.12
▲+4.92%
MU
$791.37
▼-2.46%
AVGO
$365.04
▲+5.74%
SPCX
$143.30
▲+2.54%
SNDK
$942.18
▼-3.63%
NBIS
$129.04
▼-16.58%
GOOGL
$301.46
▲+2.73%
NVDA
$164.96
▼-5.05%
AMD
$580.12
▲+4.92%
MU
$791.37
▼-2.46%
AVGO
$365.04
▲+5.74%
SPCX
$143.30
▲+2.54%
SNDK
$942.18
▼-3.63%
NBIS
$129.04
▼-16.58%
GOOGL
$301.46
▲+2.73%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Forma Therapeutics Holdings, Inc. - Common Stock
(NQ:
FMTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 13, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Forma Therapeutics Holdings, Inc. - Common Stock
< Previous
1
2
Next >
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease
September 30, 2022
From
Forma Therapeutics, Inc.
Via
Business Wire
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
September 27, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
September 02, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
FMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to Shareholders
September 01, 2022
From
Halper Sadeh LLP
Via
Business Wire
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
September 01, 2022
From
Forma Therapeutics
Via
Business Wire
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 05, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
July 29, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 12, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Appointment of New Executive Team Members
June 30, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
June 10, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at the Jefferies Healthcare Conference
June 03, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 26, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
April 29, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
February 23, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
February 08, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
January 13, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 07, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
December 16, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
December 11, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
December 09, 2021
From
Forma Therapeutics
Via
Business Wire
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
November 30, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
November 05, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
November 04, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
October 07, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Participate in Upcoming Investor Conferences
September 17, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
August 06, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
June 14, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
< Previous
1
2
Next >
